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ABSTRACT
The constitutive androstane receptor (CAR) is a xenobiotic
sensor expressed in hepatocytes that activates genes involved
in drug metabolism, lipid homeostasis, and cell proliferation.
Much progress has been made in understanding the mechanism
of activation of human CAR by drugs and xenobiotics. However,
many aspects of the activation pathway remain to be elucidated.
In this report, we have used viral constructs to express human
CAR, its splice variants, and mutant CAR forms in hepatocytes
from Car2/2 mice in vitro and in vivo. We demonstrate CAR
expression rescued the ability of Car2/2 hepatocytes to respond
to a wide range of CAR activators including phenobarbital.
Additionally, two major splice isoforms of human CAR, CAR2
and CAR3, were inactive with almost all the agents tested. In
contrast to the current model of CAR activation, ectopic CAR1 is
constitutively localized in the nucleus and is loaded onto
Cyp2b10 gene in the absence of an inducing agent. In studies
to elucidate the role of threonine T38 in CAR regulation, we found
that the T38D mutant was inactive even in the presence of CAR
activators. However, the T38A mutant was activated by CAR
inducers, showing that T38 is not essential for CAR activation.
Also, using the inhibitor erlotinib, we could not confirm a role for
the epidermal growth factor receptor in CAR regulation. Our data
suggest that CAR is constitutively bound to gene regulatory
regions and is regulated by exogenous agents through a
mechanism which involves protein phosphorylation in the
nucleus.
Introduction
TheConstitutive AndrostaneReceptor (CAR) is amember of
the ligand-activated superfamily of nuclear receptor tran-
scription factors (Kobayashi et al., 2015). Early work demon-
strated that it was the transcription factor responsible for the
induction of hepatic drugmetabolising enzymes in response to
phenobarbital (PB) treatment (Dumas et al., 1994; Forman
et al., 1998;Honkakoski et al., 1998). CAR is now recognized as
a key factor in the reprogramming of hepatic gene expression
on exposure to a wide range of drugs and environmental
chemicals, involving not only the induction of many drug
metabolising enzymes and drug transporters, but also pro-
teins involved in lipid, glucose and energy homeostasis, as well
as cell proliferation (Shah et al., 2014; Kobayashi et al., 2015).
CAR thus substantially regulates liver physiology.
Relatively few activators of human CAR have been reported
(Dring et al., 2010; Lynch et al., 2015), which can in part be
ascribed to species differences between human CAR and its
rodent counterparts (Omiecinski et al., 2011), both in ligand
specificity as well asmRNA alternative splicing. In addition to
canonical CAR1, at least two additional isoforms, CAR2 and
CAR3, are reported to be functional in man (Auerbach et al.,
2003). Furthermore, many CAR activators also activate the
pregnane X receptor (PXR) resulting in induction of the same
proteins. These complexities have been partially overcome by
the development of mouse lines humanized for CAR, for
example on a Pxr null background (Scheer et al., 2008).
Although informative, these in vivo systems are not ideally
suited to the screening of large numbers of compounds. This
has galvanised efforts to establish immortalized in vitro and
cell-based reporter assays for CAR. However, such assays are
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limited as they are unable to detect some bona fide CAR
activators, including PB, due to the requirement for hepato-
cytes to retain differentiated functions.
There has been significant progress in understanding the
mechanisms of CAR activation by exogenous agents (Negishi,
2017). CAR can be activated by either direct ligand binding
by 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbalde-
hyde-O-(3,4-dichlorobenzyl)oxime (CITCO) (Maglich et al.,
2003) or indirectly by PB. In the currently accepted model
for CAR activation, (Shizu et al., 2017), the inactive transcrip-
tion factor is a cytoplasmic homodimer phosphorylated at T38.
The homodimer is stabilized by signaling through the Epider-
mal Growth Factor Receptor (EGFR) pathway. PB exposure
inhibits the effects of EGFR and destabilizes the complex,
converting CAR into amonomer, exposing phospho-T38 which
is then de-phosphorylated by the Protein Phosphatase
2 (PP2A)/Receptor of Activated Protein Kinase C 1 (RACK1)
phosphatase complex, resulting in CAR translocation to the
nucleus and transcriptional activation. Direct-binding CAR
activators, such as CITCO, induce CAR monomerisation as a
consequence of binding to the CAR protein (Yang and Wang,
2014; Negishi, 2017).
Although data supporting this mechanism of CAR regula-
tion is quite compelling, a number of questions remain. Is
nuclear CAR constitutively active or does it require further
activation? There is evidence that nuclear translocation alone
is insufficient for CAR activation and other as yet to be defined
signaling processes are required for activation (Rencurel et al.,
2005; Koike et al., 2007; Ohno et al., 2014).Moreover, how does
PB inhibit EGFR? Is EGFR inhibition a pre-requisite for all
indirect CAR activators? Do other EGFR inhibitors activate
CAR? Also, does the proposed mechanism apply to the
putatively active human CAR splice variants?
To gain further insight into the mechanism of gene regula-
tion by CAR we have used a model hepatocyte system
involving Car2/2 mice transduced in vitro or in vivo with
viral vectors expressing native or mutant human CAR
proteins. We validate the model and show that the two major
non-canonical CAR splice isoforms, CAR2 and CAR3, are
cytoplasmic and functionally inactive. Importantly, we also
provide evidence that questions the current model of CAR
activation. Specifically, we find that CAR1 isoform is consti-
tutively present in the hepatocyte nucleus and bound to
regulatory regions of the CAR-responsive gene, Cyp2b10. We
also provide evidence that CAR activators must further
modify nuclear CAR to induce gene expression in a manner
which does not involve the phosphorylation of T38, as the
T38A mutant still required activation. The EGFR inhibitor
erlotinib did not activate CAR, questioning the role of EGFR in
regulating CAR activation.
Materials and Methods
Chemicals, Antibodies, and Recombinant Proteins. Unless
otherwise stated, all chemicals were purchased from Sigma-Aldrich
(Dorset, UK). CITCOwas obtained fromTOCRISBioscience (Abingdon,
Oxfordshire, UK). Okadaic acid (OA) and erlotinib were both from
Calbiochem (Merck, Watford, Herts, UK). Mouse anti-FLAG antibody
(clone M2) was from Sigma. Rabbit anti-FLAG antibodies conjugated
to Alexa Fluor 555 were from Cell Signaling technology (NewEngland
Biolabs, Hitchin, Herts, UK). Rabbit antibodies against: rat CYP2B1,
CYP3A1 and CYP4A1 have been previously described, and have been
shown to cross-react specifically with the corresponding murine P450
enzymes (Forrester et al., 1992; Henderson et al., 2003; Scheer et al.,
2014). Antibodies against glucose regulated protein 78 (GRP78) were
from Abcam (Milton, Cambridge, UK). Recombinant Cyp2b10 and
Cyp3a11 were prepared as previously described (McLaughlin et al.,
2008).
Animal Husbandry and Reconstitution with Human CAR
Proteins. All animal workwas carried out in accordancewith theUK
government’s Animal Scientific Procedures Act (1986). All animal
studies were approved by the Ethical Review Committee, University
of Dundee. Efforts were made to limit the number of subjects and
minimize animal suffering according to the principles of reduction,
replacement and refinement in experimental design.
Unless otherwise stated, female mice on a C57BL/6NTac back-
ground, aged between 8 and 16 weeks, were used in these studies.
Homozygous Car2/2 mice, and mice humanized for PXR and/or CAR
have already been described, as have the relevant genotyping
protocols (Scheer et al., 2008). We also used Car2/2 mice containing
a CYP2B6-LacZ reporter gene (construction of the CYP2B6-LacZ
reporter mouse is described In Supplemental Information). Finally,
we used double-humanizedhCAR/hPXRmice containing theCYP2B6-
LacZ reporter gene.
All animals were bred at the University of Dundee, School of
Medicine’s Animal Unit and were housed in Tecniplast Sealsave
microisolator cages containing Eco-Pure chip7D (Datesand Group,
Manchester, UK) for bedding. Cages also contained red polycarbonate
huts (Datesand Group). Mice were segregated by gender and housed
with siblings. Food (RM1 pelleted diet supplied by Special Diet
Services Ltd, Stepfield, Witham, Essex, UK) and drinking water
(taken from the local supply) were available ad libitum. Light cycles
were on a 12:12 hour light:dark cycle with the light phase starting at
0600 hour. Temperature and relative humidity were maintained
between 21 and 23°C, and 45% and 65%, respectively. To reconstitute
Car2/2 mice with human CAR proteins, mice were injected with 2 
109 infectious units of the appropriate adenovirus through the tail-
vein. Mice were dosed with chemicals not less than 24 hour after virus
injection to allow time for transgene expression. Mice were not fasted
and all interventions were performed during the light cycle.
Culture and Treatment of Mouse Primary Hepatocytes.
Mouse primary hepatocytes were isolated from female Car2/2
CYP2B6-LacZ reporter mice by a two-step collagenase perfusion
method and cultured, as previously described (Klaunig et al.,
1981a,b), with modification. Briefly, after perfusion with buffer
(137 mM NaCl, 7 mM KCl, 0.7 mM Na2HPO4, 10 mM HEPES, and
5.1 mM CaCl2, pH7.65) containing type I collagenase (from Clostrid-
ium histolyticum type IV; Sigma), and filtration through a 70 mm cell
strainer, hepatocytes were suspended in William’s medium E supple-
mented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine and
30 mM pyruvate and were allowed to adhere to six-well (1  106 cells)
or 12-well plates (4 105 cells) for 4 hours in a CO2 incubator at 37°C.
Plates had been pre-coated with 12.5 mg/cm2 rat-tail collagen type I
(Gibco, ThermoFisher Scientific, Perth, UK). Subsequently, the
William’s medium was replaced with serum-free HepatoZYME-SFM
containing 5 mg/ml rat-tail collagen type I and adenovirus particles.
The multiplicity of infection (MOI) for each viral preparation
(AdCAR1: 5; AdCAR2: 12; AdCAR3: 12; AdCAR1T38A: 25;
AdCAR1T38D: 20; empty adenovirus: 20) was chosen to ensure equal
expression of the various heterologous CAR proteins. Post-infection
(24 hours), hepatocytes were shifted to adenovirus- and collagen-free
HepatoZYME-SFM medium containing test compounds or vehicle
control. After 24 hour of chemical treatment, LacZ activity was
measured using the Galacto-light Plus system (ThermoFisher Scien-
tific), according to the manufacturer’s instructions.
Immunofluorescent Detection of FLAG-Tagged CAR. To
visualize FLAG-tagged CAR protein, mouse primary hepatocytes
isolated from Car2/2mice were cultured in six-well plates containing
a glass coverslip coated with rat-tail type I collagen (Gibco), infected
with adenoviral particles expressing FLAG-tagged CAR, and exposed
to chemicals as described above. Post-treatment, coverslips were
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washed twice at room temperature with PBS and fixed for 20 minute
in 4% (w/v) paraformaldehyde. After blocking and permeabilizing the
cells for 1 hour at room-temperature in a solution of 5% (v/v) fetal
bovine serum and 0.3% (v/v) Triton-X-100 in PBS, they were stained
overnight at 4°C with 10 mg/ml of AlexaFluor 555-conjugated rabbit
anti-FLAG in PBS. Coverslips were subsequently rinsed three times
in PBSwith 0.1% (v/v) TritonX-100 at room temperature andmounted
with Vectashield mounting medium with 49,6-diamidino-2-
phenylindole (Vectashield). Images were captured by confocal micros-
copy using the Leica S5 microscope equipped with a 40 NA 1.25
PlanApochromat oil-immersion objective. Fluorescent signals of
AlexaFluor-555 (excitation 543 nm using a HeNe1 laser) and 49,6-
diamidino-2-phenylindole (excitation 405 nm using a UV laser) were
detected using PMTs with spectral ranges of 551–608 nm and 427–
485 nm, respectively. Images were rendered in ImageJ.
Quantitative PCR (qPCR). Quantitative PCR assessment of
hCAR-FLAG chromatin enrichment at the Cyp2b10 locus was per-
formed using Fast SYBR Green Master Mix (Applied Biosystems
(ThermoFisher Scientific, Perth, UK)), according to the manufac-
turer’s instructions. Cyp2b10 primers were designed to encompass
accessible regulatory regions upstream of theCyp2b10 transcriptional
start site (TSS). Additional Cyp2b10 intragenic as well as control
genomic regions (homeobox A9 (Hoxa9), glyceraldehyde-3-phosphate
dehydrogenase (Gapdh)) were selected as negative control regions. All
primers are listed in Supplemental Table S1. The specificity and
quality of amplification was controlled for each of the PCR primer sets
used in this study (data not shown). To calculate enrichment level, the
amount of qPCR product in the immunoprecipitate was expressed as a
percentage of the amount of product in the input DNA. Results were
normalized using one of the negative control primer set, Gapdh.
Additional Experimental Procedures, including construction of
recombinant adenovirus’, generation of CYP2B6-LacZ reporter
mouse, in situ b-galactosidase staining, preparation of protein
extracts and immunoblotting, and Chromatin Immunoprecipitation
(ChIP), can be found in Supplemental Text.
Results
Hepatic Expression of Functionally Active Human
CAR Isoforms in CAR2/2 Mice. Analysis of liver micro-
somes from Car2/2 mice infected with either empty control
adenovirus or adenovirus’ expressing CAR isoforms showed
that all the human CAR isoforms were expressed (Fig. 1A).
None of the isoforms displayed constitutive activity as
assessed by the expression of two CAR target genes, Cyp2b10
and Cyp3a11 (Fig. 1A). Moreover, in agreement with the
literature (Jinno et al., 2004), CAR1, but not CAR2 or CAR3,
was activated by the indirect acting PB (Fig. 1A). CITCO, a
direct-acting CAR ligand, induced hepatic Cyp2b10 or
Cyp3a11 also only in mice expressing CAR1 (Fig. 1B), despite
being reported to activate all CAR isoforms on the basis of
in vitro transactivation assays (Auerbach et al., 2005). These
data demonstrate that human CAR variants can be expressed
in mouse liver using a viral delivery system and that CAR1
responds to both direct and indirect CAR activators.
To establish whether CAR2 or CAR3 were active toward
other inducers, we tested whether the Peroxisome
Proliferator-Activated Receptor a (PPARa) agonist diethyl-
hexyl phthalate (DEHP – reported to be a specific activator of
CAR2 (DeKeyser et al., 2009) would induce Cyp2b10 and
Cyp3a11. AlthoughDEHP administration induced the expres-
sion of PPARa-regulated Cyp4a11, no induction of Cyp2b10
and Cyp3a11 was observed (Fig. 1C). To investigate this
further, we treated mice humanized for CAR, (expressing all
three CAR variants (Scheer et al., 2008)), with various doses of
DEHP. In agreement with our reconstitution system, DEHP
activated PPARa (Cyp4a) but not CAR (Cyp2b10) (Fig. 2).
Human CAR Activation in Mouse Primary Hepato-
cytes. To study the mechanism of CAR activation we
expressed human CAR proteins in freshly isolated Car2/2
hepatocytes. For in vitro measurement of CAR activity, we
used hepatocytes from a Car2/2 mouse line that additionally
carried a CAR-responsive human CYP2B6-lacZ reporter. This
CYP2B6-LacZ reporter was highly inducible in mice treated
with three CARactivators (PB, phenytoin, and carbamazepine
(Fig. 3A)), but was not inducible in hepatocytes from CAR null
mice (unpublished), By titrating the multiplicity of infection
for each adenovirus preparation equivalent expression of the
three CAR splice variants was obtained (Fig. 3B). None of the
three CAR isoforms had any basal activity, as assessed using
the CYP2B6 reporter (Fig. 3C). On treatment of the CAR-
expressing hepatocytes with PB or CITCO, a robust increase
in LacZ expression was observed in CAR1 expressing cells,
whereas DEHP failed to induce LacZ activity in cells express-
ing any of the CAR isoforms (Fig. 3C). We next studied eight
additional chemicals previously investigated for their capacity
to activate some or all of the human CAR isoforms. These
included four phthalates (4-nonylphenol, reported to solely
activate CAR1 (DeKeyser et al., 2011) or CAR3 (Dring et al.,
2010), 4-octylphenol, 4-tert-butylphenol (CAR2 activator
(Dring et al., 2010)) and bisphenol-Z (CAR3 activator (Dring
et al., 2010)); trans-stilbene oxide (CAR2 activator (Dring
et al., 2010)); two anticonvulsants, phenytoin and carbamaze-
pine both of which induce CYP2B6 expression in human
hepatocytes (Faucette et al., 2007; Hariparsad et al., 2008);
and the antihistamine pheniramine, a putative CAR3-specific
ligand (Dring et al., 2010). Consistent with our in vivo
experiments (Fig. 3A), only two – PHN and CMZ – activated
CAR1 (Fig. 3C). CAR2 and CAR3 were essentially inactive for
all chemicals tested apart from a very slight activation of
Fig. 1. Expression of human CAR isoforms and P450 induction in Car2/2
mice. Car knock-out mice were injected on day 0 with either empty
adenovirus (-) or adenovirus expressing FLAG-tagged human CAR1,
CAR2, or CAR3. The mice were subsequently dosed with 80 mg/kg PB ip
(A), 50 mg/kg CITCO ip (B) or (C) DEHP at 150 mg/kg ip on each of days 1,
2, and 3. Animals were sacrificed on day 4. Liver microsomes from each
animal were pooled (n = 3) and equal amounts of protein blotted for CAR
target proteins (Cyp2b10 and Cyp3a11). The final track in the Cyp2b10
and Cyp3a11 blots contains positive standards (liver microsomes prepared
fromPB (Cyp2b10) or rifampicin (Cyp3a11) treated wild-typemice). Grp78
was used as a loading control. Whole-cell lysates were blotted for FLAG-
tagged CAR.
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CAR3 byCITCO (Fig. 3B). These data suggest that of the three
tested isoforms, CAR1 is the only functional isoform of
pharmacological significance.
CAR1 Is Constitutively Localized in the Nucleus.
According to currentmodels, CAR is retained in the cytoplasm
until activated by inducing agents (Yang andWang, 2014). To
investigate this, we carried out immunocytochemistry using a
FLAG antibody on cells infected with adenoviral CAR1.
Surprisingly, CAR1 was almost exclusively nuclear in the
majority of hepatocytes in the absence of a CAR activator (Fig.
4). On the basis of DAPI staining, there was some suggestion
that the transcription factor is specifically excluded from
nucleoli (Fig. 4). In a small percentage of cells, CAR1 was
found outside the nucleus, near the plasma membrane and/or
in punctate structures in the cytoplasm (Supplemental Fig.
S1). Although only a very small proportion of all CAR1-
expressing cells, this population is prominent as the CAR1
signal was more intense in this population than in cells
displaying nuclear CAR1. In contrast, CAR2 and CAR3
isoforms were only located in the cytoplasm of all cells, with
a punctate distribution (Fig. 4).
Upon PB treatment, CAR1 was located exclusively in the
nucleus with no minor population exhibiting cytoplasmic
localization observed (Fig. 4), suggesting that PB induces
CAR1 translocation from the cytoplasm to the nucleus in these
cells. Notably, the cytoplasmic location of both CAR2 and
CAR3 remained unaffected by exposure to PB, consistent with
their inability to induce gene expression (Fig. 4).
On the basis of its nuclear localization, we considered the
possibility that CAR1 might be constitutively bound to
chromatin at regulatory genomic binding sites, such as the
Cyp2b10 promoter and regulatory regions, in the absence of an
activator. Accordingly, we transfected Car2/2 mice with
FLAG-tagged CAR1 and the mice were either left untreated
(Supplemental Table S2 – Group A) or treated with PB for
3 days (Supplemental Table S2 – Group B). As negative
controls, we transduced the livers of Car2/2 Pxr2/2 double
humanized mice with empty adenovirus (Supplemental Table
S2 –Group E). ChIP experiments with an anti-FLAG antibody
were used to detect the presence of chromatin-bound FLAG-
tagged CAR1 in these liver samples. PCR primers were
designed to encompass accessible regulatory regions (DNase
I-sensitive and bound by transcription regulators) flanking
the Cyp2b10 transcriptional start site (TSS) (Fig. 5A; Supple-
mental Table S1). ChIP-qPCR evaluations of CAR1-FLAG
binding in individual experimental samples demonstrated
CAR1 enrichment in the absence of PB treatment in two out of
three animals tested (A3 and A2), with apparent preferential
enrichment at the proximal and distal Cyp2b10 regulatory
regions (Fig. 5B). In four out of five individual experimental
samples from PB-treated animals, (PB treated, B4 . B5 .
B2 . B1) CAR1 was enriched in at least at one of the
Cyp2b10 regulatory regions (Fig. 5B). Importantly, no
enrichment was detected in any of the negative control
samples (Fig. 5B). The limit of detection for enrichment is
set by the signal detected using negative controls regions
such as Intragenic Cyp2b10 or Hoxa9 (dotted line). Alto-
gether, these experiments demonstrate the constitutive
chromatin binding of hCAR1 at Cyp2b10 regulatory re-
gions, in the absence of PB treatment.
Studies on the Role of T38 in Car Activation. The
finding that CAR1 was localized at high levels in the nucleus
in untreated cells led us to investigate the role of T38 in CAR1
regulation as in themodel proposed byNegishi et al. it controls
CAR nuclear translocation in the presence of an inducing
agent (Negishi, 2017). In contrast to literature reports,
expression of CAR1 bearing a non-phosphorylatable alanine
residue in place of T38 (T38A) in hepatocytes did not result in
induction of CAR responsive genes (Fig. 6). Instead, it was
indistinguishable from the wild-type protein in both in terms
of inducibility (cf Fig. 3B; Fig. 6) and subcellular distribution
i.e., predominantly nuclear (Fig. 7) with occasional cytoplas-
mic staining in untreated cells (Supplemental Fig. S1). These
data provide evidence that dephosphorylation of T38 alone is
not sufficient to activate CAR1, and also suggest that both
indirect and direct-acting compounds are able to activate
CAR1 by a mechanism other than promoting T38
dephosphorylation.
To investigate this further we studied the properties of
CAR1T38D, a mutated form of CAR1 where the negatively-
charged aspartic acid mimics phosphorylated T38. This
amino-acid change is also predicted to reduce the ability of
the nuclear receptor to bind DNA (32). Consistent with the
reported central role of this phosphorylation event in CAR
function (32), CAR1T38D lacked transcriptional activity even
after stimulation by PB or any of the other CAR activators
tested (Fig. 6). However, in contrast with previous reports that
CAR1T38D is sequestered in the cytoplasm in healthy and
stimulated hepatocytes (Mutoh et al., 2009), the subcellular
distribution of this form of the protein was indistinguishable
from the wild-type protein in control and PB-treated hepato-
cytes (Fig. 7), including a complex cytoplasmic distribution in
a prominent minor subpopulation of control – but not
PB-treated – cells (Supplemental Fig. S1).
The above findings suggest that cytoplasmic retention is not a
key factor in controlling CAR activity. PB has been reported to
promote CAR1 translocation to the nucleus by inhibiting EGFR
and consequently promoting de-phosphorylation of T38 (Mutoh
et al., 2013). We reasoned that if inhibition of EGFR was
necessary and sufficient for activation of CAR1 by PB, then
inhibition of EGFRby other drugs should also activateCAR.We
found that although treatment of hepatocytes with the EGFR
inhibitor erlotinib alone abrogated EGFR signaling (Supple-
mental Fig. S2A), it did not stimulate CAR transcriptional
activity (Supplemental Fig. S2B. Indeed, pre-treatment of
hepatocytes with this inhibitor actually antagonized the acti-
vation of CAR by PB by a modest but statistically significant
extent (Supplemental Fig. S2B). Moreover, we were unable to
demonstrate any inhibition of EGFR by PB as determined by
loss of Erk1/2 phosphorylation (Supplemental Fig. S2A). These
Fig. 2. DEHP does not activate human CAR isoforms. hCAR/hPXR double-
humanized mice were treated with the indicated doses of DEHP (mg/kg) on
each of days 1, 2, and 3. Animals were sacrificed on day 4. Liver microsomes
from each animal were pooled (n = 3) and equal amounts of protein blotted for
CAR target proteins (Cyp2b10 and Cyp3a11). The final track in the Cyp2b10
and Cyp3a11 blots contains positive standards (liver microsomes prepared
from PB (Cyp2b10) or rifampicin (Cyp3a11) treated wild-type mice).
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data show that EGFR inhibition per se does not play a major
role in controlling CAR1 activation by PB. However, protein
phosphorylation does appear important as, consistent with
previous reports (34), pre-treatment of hepatocytes with oka-
daic acid, a PP2A-specific phosphatase inhibitor, reducedCAR1
activity in PB treated cells (Supplemental Fig. S2B).
Fig. 4. CAR1 is primarily nuclear in both control and
PB-treated primary mouse hepatocytes. The photomicro-
graphs depict the location of FLAG-tagged CAR isoforms in
mouse primary hepatocytes 24 hour after treatment with
vehicle (PBS) or 2.5 mM PB. DAPI was used as a nuclear
counterstain. Scale bar, 50 mm.
Fig. 3. Human CAR activity can be mea-
sured ex vivo in primary mouse hepato-
cytes. (A) Male C57BL/6 mice from a
transgenic reporter model where murine
Car and Pxr are replaced with their
human counterparts CAR and PXR, and
bearing a CYP2B6-LacZ reporter trans-
gene,were treatedwith phosphate-buffered
saline (PBS; Vehicle), phenobarbital (PB;
80 mg/kg), phenytoin (PHN; 50 mg/kg) or
carbamazepine (CMZ; 250 mg/kg) intra-
peritoneally (ip) at 5ml/kg, daily for 3 days
(n = 3). Representative liver sections
stained for LacZ are shown. (B and C)
Hepatocytes from Car2/2 CYP2B6-LacZ
reporter mice were reconstituted with
empty control adenovirus (-) or adenovi-
ruses expressing human CAR isoforms
or mutants thereof. (B) Expression of
FLAG-tagged proteins was determined
by immunoblot. (C) CYP2B6-LacZ re-
porter activity (RLU/mg protein) wasmea-
sured 24 hour after exposure to the
indicated chemicals. All chemicals were
used at a final concentration of 10 mM
except PB (2.5 mM), phenytoin (20 mM),
carbamazepine (25 mM), DEHP (50 mM),
and trans-stilbene oxide (50 mM). Data
represent the mean 6 S.D. of three sepa-
rate experiments.
Evidence CAR is Constitutively Nuclear 5
 at A











CAR was first isolated as a key regulator of hepatic drug
metabolising enzymes in response both to drugs and environ-
mental chemicals. However, it also controls a number of other
important hepatic functions. Understanding CAR regulation
and the downstream consequences is of central importance in
understanding hepatocyte function and also in predicting
drug/drug interactions and pathways of drug and chemical
toxicity (Luisier et al., 2014; Yang andWang, 2014). It could be
argued that regulation of CAR in mice differs from that in
humans; however, the system used recapitulates the mecha-
nism of gene regulation by known CAR activators and based
on our current knowledge, although species differences in
ligand specificity and in the downstream genes they regulate
have been described, to date no differences in the mechanism
of CAR regulation have been reported.
Mechanistic insights into CAR regulation have been pio-
neered by Negishi (2017). The data presented in this paper
Fig. 5. CAR1 is pre-bound at the Cyp2b10 promoter in untreated hepatocytes. (A) Depiction of the location of PCR amplicons in and upstream of the
Cyp2b10 gene that were chosen for use in ChIP analysis of chromatin occupancy by FLAG-tagged CAR1. The track displays publically-available, DNase I
hypersensitivity data for C57BL/6 liver (ENCODE ENCSR000CNI, replicate 1) and highlights that the chosen amplicons fall within DNase I-sensitive
regions of chromatin. (B) Enrichment of Cyp2b10 proximal and distal amplicons, and negative control amplicons (Cyp2b10 intragenic region, Hoxa9,
Gapdh) in anti-FLAG-immunoprecipitates from untreated mice reconstituted with CAR1 (Group A), PB-treated mice reconstituted with CAR1 (positive
control samples – Group B), or untreated mice reconstituted with empty virus (negative control samples – Group E). Enrichment data are presented for
individual mice and are normalized to the Gapdh signal. The horizontal dashed-line represents the limit of detection for enrichment.
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extends some of this work and questions certain aspects of the
current model. In the first instance, contrary to data obtained
using in vitro transactivation assays with transformed non-
hepatic cell lines (DeKeyser et al., 2009, 2011; Dring et al.,
2010) the splice variants CAR2 and CAR3, which only differ
from CAR1 by three and five amino acids respectively
(Auerbach et al., 2003), were inactive toward essentially all
the compounds tested apart from a very minor activation of
CAR3 by CITCO. The reason for this difference between our
findings and published data are unclear but probably relates
to the different cells used, i.e., between primary hepatocytes
and immortalized non-hepatocyte cell lines. It is relevant to
note that unlike CAR1, both CAR2 and CAR3 were located in
the cytoplasm in the presence and absence of the CAR
inducing agent PB, (with the caveat that PB did not activate
CAR2 or CAR3). It is interesting to note that DEHP at doses
which activated PPARa, were inactive toward all three CAR
isoforms) in vivo. These data show that the small amino acid
differences in CAR sequence determine its subcellular local-
ization and also explains why the splice variants are essen-
tially inactive.
The finding that the majority of expressed CAR1 was in the
nucleus in the absence of chemical activators is in contrast
with a number of studies reported in the literature (Yang and
Wang, 2014; Negishi, 2017). However, it is consistent with the
finding that the vitamin D receptor (Bertrand et al., 2004), the
nuclear receptor most closely related to CAR, is also located in
the nucleus (Haussler et al., 1998). Indeed, this location is also
a characteristic of other unliganded Class II-type nuclear
receptors, of which CAR is one (McKenna andO’Malley, 2002).
The direct evidence that endogenous CAR1 is cytoplasmic,
i.e., which does not use tagged CAR1 proteins to track CAR1
localization, comes from subcellular fractionation experi-
ments. This approach has its own limitations in that nuclear
proteins, including nuclear receptors, have been shown to
distribute into the cytosolic fraction on differential centrifu-
gation (Yamamoto, 1985).
Wild-type CAR1 and both of the T38 mutant forms were
almost exclusively in the nucleus. If this was due to the over-
expression of CAR, a combination of both cytoplasmic and
nuclear staining would have been expected – this was not the
case. The difference between our findings on CAR localization
and those reported in the literature could be due to the
expression of the much smaller FLAG- versus GFP-tagged
CAR (Guo et al., 2007; Mutoh et al., 2009). In both cases, the
expression of CAR was at higher than physiologic levels,
which therefore would not explain the difference in the data.
Also, if this was the case in our experiments it would not
explain why CAR2 and CAR3, when expressed at the same
level, were located in the cytoplasm. The nuclear localization
of CAR was also supported by ChIP analyses, which showed
that CAR1 was constitutively bound to proximal and distal
regions of the Cyp2b10 gene in mouse liver in vivo. Interest-
ingly, CAR1 binding was at novel regions of the gene and
enrichment was not observed at the Cyp2b10 transcription
start site containing the Phenobarbital-responsive Element
Fig. 7. Residue T38 is dispensable for correct CAR1
localization in primary mouse hepatocytes. Photomicro-
graphs depict the location of FLAG-tagged CAR1 bearing
amino-acid substitutions at residue T38 in mouse primary
hepatocytes 24 hour after treatment with vehicle (PBS) or
2.5 mMPB. DAPI was used as a nuclear counterstain. Scale
bar, 50 mm.
Fig. 6. CAR1T38A is not constitutively active. Hepatocytes from Car2/2 CYP2B6-LacZ reporter mice were reconstituted with empty control adenovirus
(-) or adenoviruses expressing human CAR1T38A or CAR1T38D. CYP2B6 reporter activity (RLU/mg protein) was measured 24 hour after exposure to the
indicated chemicals. All chemicals were used at a final concentration of 10 mM except PB (2.5 mM), phenytoin (20 mM), carbamazepine (25 mM), DEHP
(50 mM), and trans-stilbene oxide (50 mM). Data represent the mean6 S.D. of three separate experiments. Note that these data were collected alongside
the data presented in Fig. 3C; the empty control adenovirus data are shared between the two datasets.
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Module (PBREM). Preliminary data using DNaseI finger-
printing on in vivo samples showed that the endogenous
Car1 protein is bound constitutively to the Cyp2b10 promoter
(Terranova, et al., unpublished data).
In a small number of cells CAR1 expressionwas cytoplasmic
and it is possible that these are cells in which CAR1 becomes
activated by exogenous chemicals in a manner which is
consistent with the findings of Negishi et al. Indeed, cytoplas-
mic CAR1 staining was no longer detected on the administra-
tion of the CAR activator phenobarbital. However, it is
unlikely that this small number of cells could account for the
transactivation responses observed. Although it should be
noted that there may not be a direct relationship between the
observed level of nuclear receptor and the degree of trans-
activation. Also, if this were the case, it would not explain why
nuclear CAR1 was not constitutively active. It will be in-
teresting to establish what distinguishes these hepatocytes
from the rest of the population. It should be noted that Negishi
and co-workers have recently also shown constitutive CAR
1 nuclear localization (Shizu et al., 2017) and independent of
differences in the reports our data demonstrates that the
sequestering of CAR in the cytoplasm is not a key factor in
supressing its activity.
A major advance in understanding the mechanism of CAR
activation was the identification of T38 as a critical amino acid
in this process. Themost recent model proposed that phospho-
T38 retains CAR in the cytoplasm in a dimeric form which is
converted to a monomer on exposure of hepatocytes to either a
direct ligand or indirect-acting activators. This results in the
removal of the phosphate group which facilitates nuclear
translocation (Mutoh et al., 2009; Negishi, 2017). However,
our data demonstrates that T38 is dispensable for CAR1
activation as the CAR1T38A mutant was not constitutively
active and required an exogenous activator to become func-
tional. Our finding that the T38D mutant is inactive suggests
that T38 is an important structural amino acid.
A major unifying mechanism of nuclear receptor function is
that activation, for example by a ligand, increases transcrip-
tional activity by increasing the affinity for nuclear coactiva-
tors by ligand-induced conformational changes in the
receptors (McKenna and O’Malley, 2002). It is now also clear
that these interactions can be modulated by signal trans-
duction pathways that lead to phosphorylation of either
coactivator complexes or nuclear receptors themselves
(Gronemeyer et al., 2004). Our studies suggest that PB
promotes the interaction of CAR with one-or-more coactivator
complexes to activate transcription. Consistent with this
hypothesis was our finding and those of others that the
phosphatase inhibitor okadaic acid inhibited the action of
PB (Honkakoski and Negishi, 1998). Moreover, an increased
interaction with a coactivator complex may explain the re-
distribution of CAR1 in hepatocytes where cytoplasmic stain-
ingwas observed (Negishi, 2017). Based on previous studies, it
is interesting to speculate that nuclear AMPKmay be involved
(Rencurel et al., 2005; Kodiha et al., 2007).
A number of compounds activate CAR by an indirect
mechanism and it has been reported that in the case of PB
this involves inhibition of EGFR signaling (Mutoh et al., 2013).
In our study PB did not inhibit EGFR, nor did the EGFR
inhibitor Erlotinib induce CAR-mediated gene expression.
These data argue against a role for EGFR in CAR transcrip-
tional activation by phenobarbital and possibly other indirect
activators. Recently, Shizu et al. reported that erlotinib
induced CAR-mediatedCyp2b10 expression, albeit only three-
fold relative to a 15-fold induction with PB (Shizu et al., 2017).
Our data suggest that signaling through MEK/ERK is not
involved in CAR activation. However, this could be further
investigated through the use of specific inhibitors and activa-
tors of this pathway.
In summary, based on the data above, our current hypoth-
esis is that CAR is constitutively bound to CAR-responsive
genes and is activated as a consequence of a phosphorylation
event of itself or co-activator proteins. The kinases and
phosphatases involved in this process remain to be identified
but AMPK may be involved. The mechanism of CAR1
activation in the nucleus remains an important area for
research; in this study, we have exemplified a powerful
experimental approach for this purpose.
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